Studies presented at the ASCO Annual Meeting 2025 highlighted immunotherapies that may provide new standards of care for certain cancers as well as immunotherapies that are breaking new ground by ...

Merus (NASDAQ:MRUS) is one of the most promising stocks according to Wall Street analysts. The 2025 Annual Meeting of the ...

Precision oncology has entered a new phase, as data sets mature and a new wave of tools emerges to help clinicians manage ...

Home-based cancer care is safe, feasible, and preferred by most patients, according to early findings from a Mayo Clinic ...

On the forefront of healthcare change, turning innovative science into value for patients: Astellas at ASCO 2025 At this year ...

Yiviva, a clinical-stage biotechnology company pioneering systems biology-driven therapeutics, announced data from its ...

If you’ve missed our conversations with other experts in the oncological field, be sure to check out our Spotlight On page ...

Research presented at the ASCO Annual Meeting 2025 highlighted potential new standards of care and other advances in ...

IOVA's ASCO update reiterates the value of Amtagvi in melanoma, but upcoming data in lung cancer and endometrial cancer in H2'25 might have a bigger ...

Targeted therapies and immunotherapy can provide benefits when added to chemotherapy or may eliminate the need for ...